


Microbiology of respiratory system Microbes present? URT? LRT? Why? 3





Respiratory tract defenses • Nasal structure Nasal hairs • Mucus • Ciliated epithelial cells • Cough reflex Secretory antibodies Normal flora


Which organisms are there as normal flora? Staphylococcus aureus Streptococcus pneumoniae Neisseria meningitidis Haemophilus influenzae "Diphtheroids" Corynebacterium spp. [not C. diphtheriae] and others (incl. Candida) **Compete for attachment sites**


Produce bacteriocidal products



















































21








22




- Virulence factors: enzymes, exotoxins, capsule, adhesins


Treatment:


- no vaccine Disease:





27






26








Exemplar: Corynebacterium diphtheriae


- toxin (inhibits protein synthesis, highly toxic, affects heart, nerves)

• Treatment:


- anti-toxin (anti-serum) to neutralize toxin
- antibiotics (erythromycin)
- vaccination (toxoid = altered form of toxin) [part of DTP vaccine] [Almost eradicated in Australia]
























| Upper respiratory tract infections | | | | |
|------------------------------------|---|--|--|--|
| Disease | Infecting organisms | Comments | | |
| Common cold | Viruses, eg Rhinoviruses | Many serotypes | | |
| Acute Otitis media | Viruses (esp. RSV) | Cause at least 50% of cases | | |
| | S. pneumoniae, H. influenzae, M. catarrhalis S. pyogenes, S. aureus | Generally secondary infection, Most commonly nasopharyngeal residents, Fluid often persists in middle ear for weeks-months (glue ears) | | |
| Acute Sinusitis | Etiology & pathogenesis similar to Acute otitis media | | | |
| Pharyngitis | Viruses | Cause approx 70% of sore throats | | |
| | Streptococcus pyogenes | 10-20% acute cases; sudden onset; mostly 5-10 yo | | |
| | Neisseria gonorrhoeae | Often asymptomatic, usually via orogenital contact | | |
| | Corynebacterium diphtheriae | Mild but toxic illness can be severe | | |
| | Haemophilus influenzae | Epiglottitis | | |
| Diphtheria | C. diphtheriae | Rare in developed countries (immunisation) | | |
| Acute epiglottitis | H. Influenzae type b | Organism spreads from nasopharynx to epiglottis | | |
| Laryngitis & Tracheitis | Parainfluenzae virus, RSV, GpA Strep, <i>H. influenzae, S. au</i> | Viruses cause most infections reus | | |










Penetration & contamination



























Surface glycoproteins H = haemagglutinin N = neuraminidase



Influenza


Type A (humans, animals, birds) - every 2-3 years Type B (humans only) - every 4-6 years

Overall mortality ~ 1% BUT


epidemics (pandemics) killed millions


H1N1 Spanish flu (1918) 40m deaths H2N2 Asian flu (1957) 2m deaths H3N2 Hong Kong flu (1968) 1m deaths H1N1 Russian flu (1977) no pandemic H5N1 bird flu (1997) 6 deaths

49





51






50







| Pneumonia | | | | |
|--|---------------------------------------|--|--|--|
| • Acute illness | • CURB65 (1 pt for each) | | | |
| Radiological shadowing | Confusion | | | |
| • Setting | • Urea (>7) | | | |
| • community-acquired | Respiration (>30) | | | |
| nosocomial | • Blood pressure (<90) | | | |
| aspiration | • age >65 | | | |
| immunocompromised | [4-5 pts \rightarrow 40% mortality] | | | |



57

| | Pneumonia |
|-----|--------------------------|
| Cau | ses – children |
| | Group B streptococcus |
| | RSV |
| | Chlamydia trachomatis |
| | Mycoplasma pneumoniae |
| | Influenza virus |
| Cau | ses – adults |
| | Mycoplasma pneumoniae |
| | Streptococcus pneumoniae |
| | Haemophilus influenzae |
| | - immunocompromised |
| | Gram negative organisms |





58

56

Typical pneumonias

Community acquired Streptococcus pneumoniae (most common) Haemophilus influenzae Klebsiella pneumoniae Neisseria meningitidis

Atypical pneumonias

Mycoplasma pneumoniae Chlamydia pneumoniae Legionella pneumophilis

Viruses (influenza)

Fungi

Nosocomial pneumonia

Prevalence

0.5 – 5% hospitalised patients higher in ICU, postoperative patients


Organisms

Gram -ve bacilli (microaspiration during sleep)


Antibiotic resistance Recent antibiotic therapy Longer than 2 days in hospital Immune suppression Bronchiectasis (dilation) Ventilator-associated pneumonia High mortality – 40% Causes ARDS Predisposing Endotracheal tube Muscle relaxants Pre-existing sinusitis, pharyngitis


62


61



63








Polysaccharide capsule

- >90 serotypes
- 80% of invasive disease in children caused by 7 serotypes (4, 6B, 9V, 14, 18C, 19F, and 23F)
- major virulence factor: capsule (interferes with phagocytosis)

capsular material

- Increases virulence by 100,000-fold
- Highly antigenic (immunity directed against capsule)



67

second.

people every year.

Pneumococcal vaccines


· 23-valent (Pneumovax)

- Covers the about 90% of disease in adults
- Doesn't work in children <2 years of age (because they do not respond to T cell-independent antigens)


7-valent (Prevenar)


- A new conjugated pneumococcal vaccine
- Covers about 80% of disease in children in the U.S.
- Over 90% protective against invasive disease with bacteremia. Less protective against otitis media and colonization.
- Costs \$200 \$300 US dollars/child for the recommended 4 dose series of injections.


68



69












- · Diagnosis of latent or clinically undeclared TB
- · Most useful in countries with low disease incidence
- · +ve test after recent -ve indicates recent exposure
- Injection of proteins made by *M. tuberculosis* (tuberculin)
- · Purified protein derivative (PPD) derived from broth cultures
- · Mantoux test: most accurate, delivers defined dose



75



Exceptions

· False negative reactions

- persons recently infected with TB
- elderly, debilitated and immunocompromised (e.g. AIDS) patients · May be unresponsive
- In some patients, the reaction may be negative even though TB disease is present

· False positive reactions

- may result from exposure to "atypical" mycobacteria, which cause different patterns of infection and disease
- · Important because treatment is different
- person has been vaccinated

76

Prevention of TB

• BCG vaccine (Bacille Calmette-Guerin), available since 1920's

- Attenuated bovine strain (M. bovis)
- Vaccine used in endemic regions
- Causes person to convert to positive skin test
- Not used in countries with low incidence of TB

Pros: Low cost, effective in young children.

Cons: variation in potency of live vaccines, variation in effectiveness among adults, potential for disseminated BCG in HIV infected individuals, effect on skin test reaction to tuberculin.

- · Elimination of disease highly unlikely
- · Control by active surveillance, intervention & monitoring

| | Lower respiratory tract infections | | |
|-----------------------------|---|---|--|
| Disease | Infecting organisms | Comments | |
| Bronchitis Bronchiolitis | Respiratory viruses, esp. RSV, influenza, adeno & rhinoviruses Mycoplasma pneumoniae, Streptococcus pyogenes | Malaise, headache, sore throat, fever cough (non-productive or mucopurulent), supportive therapy | |
| Whooping cough | Bordetella pertussis | mucus - inspiratory stridor (whoop) toxin, tissue damage vaccination available | |
| Influenza | Orthomyxoviruses | Haemagglutinin/Neuramidase proteins genetic mixing (bird/human in pig) variable symptoms (bronchitis-pneumonia) | |
| Pneumonia | Streptococcus pneumoniae Haemophilus influenzae Mycoplasma pneumoniae Chlamydia pneumoniae | typical/atypical disease, acute illness radiological shadowing, respiratory distress community-acquired (CUR865), nosocomial, ventilator, immunosuppressed | |
| Tuberculosis (TB) | Mycobacterium tuberculosis | primary TB, granuloma, secondary TB skin test, vaccination multi-drug resistance (extensively DR) | |

